Oncolytic virotherapies against glioblastoma multiforme

Currently, standard therapy for GBM consists of tumour resection followed by radiotherapy and concomitant TMZ which remains insufficient to mitigate the disease's deadly effects. Therefore, it has been promoted the development of alternate immunotherapies, such as oncolytic virotherapies, that are emerging as a safe and feasible treatments for a variety of malignancies.